Running for a Cure 2023: A Fundraiser for GSD1B From the Sophie’s Hope Foundation
source: shutterstock.com

Running for a Cure 2023: A Fundraiser for GSD1B From the Sophie’s Hope Foundation

Jamas and Margot LaFreniere started the Sophie's Hope Foundation in 2020 shortly after Sophie, their daughter, was diagnosed with a rare disease: glycogen storage disease type 1B (GSD1B). The mission…

Continue Reading Running for a Cure 2023: A Fundraiser for GSD1B From the Sophie’s Hope Foundation

A UConn Health Team Administers the World’s First Gene Therapy for Glycogen Storage Disease Type-1a

In January of this year, a University of Connecticut (UConn) team administered the world’s first infusion of a new gene therapy as part of a long-awaited clinical trial. According to…

Continue Reading A UConn Health Team Administers the World’s First Gene Therapy for Glycogen Storage Disease Type-1a
Experimental Treatment for Glycogen Storage Disease Type III Gets Orphan Designation in EU and US
source: pixabay.com

Experimental Treatment for Glycogen Storage Disease Type III Gets Orphan Designation in EU and US

According to a story from Market Watch, the biopharmaceutical company Ultragenyx Pharmaceutical, Inc. recently announced that it was given Orphan Drug designation from both the US Food and Drug Administration…

Continue Reading Experimental Treatment for Glycogen Storage Disease Type III Gets Orphan Designation in EU and US
DCCR Tablets for GSD1A Granted Orphan Drug Status
https://unsplash.com/photos/8ztH-7lj8ag

DCCR Tablets for GSD1A Granted Orphan Drug Status

In a news release from June 2, 2021, biopharmaceutical company Soleno Therapeutics, Inc. ("Soleno") shared an exciting update. The company's investigational treatment, DCCR (diazoxide choline) Extended-Release tablets, received Orphan Drug…

Continue Reading DCCR Tablets for GSD1A Granted Orphan Drug Status